No Data
No Data
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday.Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply during Tuesday's session following upbeat quarterly ear
Summit Therapeutics (SMMT.US) was first covered by Citi, giving it a buy rating, with a target price of $7.00.
Summit Therapeutics (SMMT.US) was first covered by Citi, giving it a buy rating, with a target price of $7.00.
Summit Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 55.56% Citigroup → $7 Initiates Coverage On → Buy 03/26/2024 77.78% Stifel → $8 Initiates Cover
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q1 2024 Earnings Conference
The following is a summary of the Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript:Financial Performance:Summit Therapeutics ended Q1 2024 with a cash balance of $157 million, projecte
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54
Summit Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.
Summit Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.